Cargene Biopharma is a preclinical-stage biopharmaceutical company developing oligonucleotide therapeutics, including highly potent, specific and stable siRNAs, for cardiovascular, fibrotic and pulmonary indications. Its proprietary OSCAR™ algorithm and SMoP™ pharmacophore design platforms are used together to rapidly design siRNAs, with initial programs focused on cardiovascular disease and non-alcoholic steatohepatitis (NASH). The company has exclusively in-licensed regenerative medicine-related technology from A*STAR aimed at reducing liver fibrosis and has demonstrated effects in acute and chronic liver disease models and human cell assays. Cargene is also developing targeted delivery technologies for oligonucleotides to multiple organs and novel nucleosides to boost siRNA efficacy. It operates in Singapore, the USA and China and is supported by a scientific board including Professors Harvey Lodish, Roger Foo, Kausik Ray and Torsten Wuestefeld. The company intends to use the recent funding to advance its lead asset toward an investigational new drug (IND) application and accelerate broader technology development.

Total raised

$19M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2021